KDR and glioblastoma: The alkaloid voacangine inhibits vascular endothelial growth factor receptor 2 (VEGFR2) preventing growth of glioblastoma; The affinity of voacangine with proteins such as AKT1 (−9.0 kcal/mol) and eNOS3 (−9.1 kcal/mol) can influence downstream the VEGFR2 signaling cascade [67,70].